Pliant Therapeutics. has filed a patent for methods of treating fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). The patent involves the administration of compounds that are avß6 integrin inhibitors, along with a second drug selected from pirfenidone and nintedanib. The compounds of interest are described by Formula (A), Formula (I), or Formula (II), and their pharmaceutical compositions. GlobalData’s report on Pliant Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Pliant Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Pliant Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Pliant Therapeutics's grant share as of September 2023 was 9%. Grant share is based on the ratio of number of grants to total number of patents.

The patent is filed for a method of treating fibrosis

Source: United States Patent and Trademark Office (USPTO). Credit: Pliant Therapeutics Inc

A recently filed patent (Publication Number: US20230293519A1) describes a method for treating a disease by administering a combination of drugs. The method involves administering a first drug, which is a compound of formula (II) or a salt thereof, and at least a second drug selected from pirfenidone and nintedanib, or a salt thereof. The compound of formula (II) has specific structural characteristics, including substituents on various carbon and nitrogen atoms. The method is intended for the treatment of diseases such as pulmonary fibrosis, interstitial lung disease, and systemic sclerosis-associated interstitial lung disease.

The patent claims also describe specific variations of the compound of formula (II) and the second drug, including different substituents and dosage forms. The first drug can be administered in various amounts, ranging from 1 to 1040 milligrams, depending on the specific condition and patient. The second drug, pirfenidone, can be administered orally in capsule or tablet form, with specific dosages and titration schedules. Nintedanib, the other second drug, can be administered orally in lipid or capsule form, with specific dosages and formulations.

The method aims to modulate integrin activity and/or expression, particularly avß6 and avß1 integrins, in order to treat the disease. The combination of drugs selectively reduces the activity and/or expression of these integrins, which are involved in fibrosis and tissue remodeling processes. The method can be used to treat various tissues affected by the disease, including lung, liver, skin, cardiac, kidney, gastrointestinal, gall bladder, and bile duct tissues.

The first and second drugs can be administered together or at different times, depending on the treatment schedule. The second drug may be administered over a period of time before initiating the first drug, and the dose of the second drug can be adjusted or discontinued based on the patient's response to treatment.

Overall, this patent describes a method for treating diseases using a combination of specific drugs, targeting integrin activity and/or expression. The method provides detailed information on the structural characteristics, dosages, and administration forms of the drugs, as well as their potential applications in various diseases.

To know more about GlobalData’s detailed insights on Pliant Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies